Learn More
2529 Background: PET offers a non invasive tool to assess cancer biology, staging tumors and potentially monitoring treatment response, anti-angiogenic therapy included. The aim of this study was to(More)
PURPOSE Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most patients with BC are node(More)
BACKGROUND Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully characterized. This study investigates(More)
BACKGROUND we previously reported a phase I trial of liposome-encapsulated doxorubicin citrate (LD), docetaxel and trastuzumab as neoadjuvant in stages II and IIIA human epidermal growth factor(More)
This retrospective trial evaluates whether the timing of initiation of the adjuvant chemotherapy has any influence over survival in early-stage breast cancer. A total of 2782 patients from El Álamo(More)